Pemphigus Vulgaris

Pemphigus Vulgaris — scientific infographic poster

Table of Contents

  1. Pemphigus Vulgaris Explained
  2. Pathogenesis: Desmoglein Antibodies
  3. Clinical Features and Presentation
  4. Diagnosis: Tests and Signs
  5. Pemphigus Variants
  6. Induction Therapy: Corticosteroids
  7. Rituximab: The Modern Standard
  8. Maintenance and Monitoring
  9. Paraneoplastic Pemphigus
  10. Prognosis and Quality of Life
  11. Key Research Papers
  12. Connections
  13. Featured Videos

Pemphigus Vulgaris Explained

Pemphigus vulgaris (PV) is a rare, potentially life-threatening autoimmune blistering disease of the skin and mucous membranes. The immune system generates immunoglobulin G (IgG) autoantibodies against desmoglein proteins — the molecular "glue" that holds skin cells together — causing them to lose cohesion and separate. The result is fragile, flaccid blisters that rupture easily, leaving raw, painful erosions that heal slowly.

A 2023 meta-analysis of 29 studies put the worldwide incidence of PV at 2.83 cases per million person-years (about 0.28 per 100,000 per year), with the highest regional rate in Southern Asia (4.94 per million person-years). Higher rates are reported in Jewish, Indian, and Mediterranean populations, where certain human leukocyte antigen (HLA) haplotypes predispose. It most commonly presents in the 4th–6th decade, affecting men and women roughly equally. Before corticosteroids were available, PV was fatal in approximately 75% of patients within 2–5 years from infections, fluid loss, and sepsis. Today, with modern immunosuppressive therapy — and particularly with the introduction of rituximab — mortality has fallen to under 5%, though the disease remains seriously disabling.

The hallmark clinical clue that distinguishes PV from other blistering disorders: oral involvement in 90% of patients, often months before skin blisters appear. Painful, stubborn mouth sores that do not respond to standard treatments are a recognised early sign that points toward PV.

Pathogenesis: Desmoglein Antibodies

Desmogleins (DSG) are transmembrane glycoproteins that form the adhesive core of desmosomes — the intercellular junctions that rivet keratinocytes (skin cells) together. Without functional desmogleins, keratinocytes lose adhesion and separate — a process called acantholysis (loss of cell-to-cell cohesion within the epidermis).

Two desmogleins are targeted in pemphigus:

The desmoglein compensation hypothesis explains the anatomical distribution: in the upper epidermis, DSG1 is abundant and can compensate if DSG3 is targeted (no skin blistering from anti-DSG3 alone). In mucosa, DSG1 is scarce so DSG3 alone provides cohesion — thus anti-DSG3 antibodies always cause mucosal disease. When both anti-DSG3 and anti-DSG1 are present, both mucosa and skin blister.

The mechanism of antibody action is direct: anti-DSG immunoglobulin G sterically blocks desmoglein-desmoglein interactions and triggers intracellular signaling cascades (involving p38 mitogen-activated protein kinase (MAPK) and RhoA) that further weaken keratinocyte adhesion. Complement activation plays a secondary role. The separation occurs just above the basal cell layer, creating the "suprabasal" split that is histologically definitive for PV.

Genetic predisposition involves human leukocyte antigen class II alleles (DRB1*0402, DQB1*0503 confer the highest risk). Environmental triggers include certain drugs (captopril, penicillamine, rifampin) and, rarely, viral infections.

Clinical Features and Presentation

Oral Mucosal Involvement (First Sign in 90%)

Oral erosions are the presenting complaint in the majority of PV patients and may precede skin blistering by weeks to months — sometimes more than a year. The erosions are painful, irregular, and slow to heal. They typically affect the buccal mucosa, gingiva, palate, and posterior pharynx. Patients frequently report difficulty eating, speaking, and swallowing. These lesions are commonly misdiagnosed as aphthous ulcers, candidiasis, or herpes before PV is considered.

Skin Blisters

Cutaneous blisters in PV are characteristically flaccid (thin-walled, easily ruptured) — in sharp contrast to the tense blisters of bullous pemphigoid, which arise beneath the epidermis and are much harder to break. PV blisters arise within the epidermis and the overlying roof is so fragile it ruptures spontaneously or with minimal trauma, leaving extensive raw erosions. Healing is slow, and secondary bacterial infection (particularly Staphylococcus aureus) is common and a major cause of morbidity.

Blisters can appear anywhere on the body but favor the scalp, face, chest, back, and intertriginous areas. The trunk is commonly involved.

Other Mucosal Sites

Beyond the oral cavity, PV can involve the conjunctiva (ocular mucosa), nasal mucosa (epistaxis, crusting), larynx (hoarseness, aspiration risk), esophagus (dysphagia), and anogenital mucosa (painful erosions).

Diagnosis: Tests and Signs

Nikolsky Sign

Lateral finger pressure on normal-appearing perilesional skin shears off the superficial epidermis, extending the blister laterally. Positive Nikolsky sign reflects active acantholysis and is highly characteristic of pemphigus (and other acantholytic disorders) — absent in bullous pemphigoid where the epidermis is firmly anchored to dermis. The Asboe-Hansen sign (pressing down on an intact blister causes it to extend laterally) is related.

Tzanck Smear

A quick bedside test: scraping the base of a freshly ruptured blister and staining with Giemsa or Wright stain reveals acantholytic "Tzanck cells" — rounded, detached keratinocytes with large nuclei and abundant cytoplasm. Positive in pemphigus but not specific (also seen in herpes infections). It can provide rapid supportive evidence while awaiting biopsy.

Skin Biopsy with Histology

Biopsy of a freshly formed blister (or blister edge) shows the pathognomonic suprabasal acantholytic split: a cleft just above the basal cell layer with tombstone-row basal cells still adherent to the basement membrane and rounded acantholytic cells floating free in the blister cavity.

Direct Immunofluorescence (DIF) — Gold Standard

Biopsy of perilesional skin stained with fluorescently tagged anti-IgG antibodies shows the characteristic "fishnet" or "chicken wire" intercellular immunoglobulin G deposition throughout the epidermis — immunoglobulin G outlining the surfaces of every keratinocyte in a network pattern. This pattern is pathognomonic for pemphigus and is the definitive diagnostic test. C3 complement may co-deposit.

Indirect Immunofluorescence and ELISA

Serum anti-DSG1 and anti-DSG3 antibody titers can be measured by enzyme-linked immunosorbent assay (ELISA). Titers correlate with disease activity and are used to monitor response to treatment and guide tapering. Rising titers may predict clinical relapse before visible blistering recurs.

Pemphigus Variants

Pemphigus Foliaceus

Anti-DSG1 antibodies only (no anti-DSG3). Because DSG1 predominates in the upper epidermis and DSG3 compensates in mucosa, PF causes superficial skin crusting without mucosal involvement. The split is subcorneal (very superficial). Blisters are fragile and rarely intact; the typical presentation is scaly, crusted erosions on the scalp, face, chest and back, without mouth sores (see Pemphigus Foliaceus).

Pemphigus Vegetans

A rare PV variant where erosions, particularly in intertriginous areas (axillae, groin), develop verrucous (wart-like), hypertrophic, vegetating plaques rather than simple erosions — thought to be a hyperplastic healing response.

Drug-Induced Pemphigus

Certain drugs can trigger a pemphigus-like syndrome: thiol-containing drugs (penicillamine, captopril) most commonly, but also angiotensin-converting enzyme inhibitors (ACE inhibitors), penicillins, cephalosporins, rifampin. Drug-induced PV may remit after drug withdrawal, though immunosuppression is often still needed acutely.

Induction Therapy: Corticosteroids

The goal of induction therapy is to rapidly suppress blister formation and achieve disease control. Before immunosuppressives, PV had 75% mortality; the introduction of systemic corticosteroids in the 1950s was transformative. Prednisone (or equivalent) remains the cornerstone of initial therapy.

Adjuvant immunosuppressants are used to allow steroid tapering (steroid-sparing effect) and reduce cumulative steroid exposure.

Rituximab: The Modern Standard

Rituximab is an anti-CD20 monoclonal antibody that depletes B lymphocytes — the precursors to the plasma cells producing pathogenic anti-DSG immunoglobulin G antibodies. It has fundamentally changed the treatment landscape for pemphigus vulgaris.

RITUX3 Trial

The landmark RITUX3 randomized controlled trial (Joly et al., 2017, Lancet) demonstrated that rituximab plus short-term prednisone outperformed long-term standard-dose prednisone for PV. At 24 months, 89% of rituximab patients were in complete remission off therapy versus 34% of prednisone-alone patients. Crucially, rituximab patients had significantly fewer corticosteroid-related adverse events. This trial established rituximab as the preferred first-line treatment for moderate-to-severe PV in many centers.

Rituximab Dosing in PV

Why Rituximab Works So Well in PV

Unlike in rheumatoid arthritis (where many cytokines drive disease), pemphigus depends specifically and almost entirely on the production of pathogenic immunoglobulin G antibodies. Depleting the B-cell compartment removes the antibody factory. Rituximab can achieve sustained complete remission in over 70–90% of patients, with some patients remaining in long-term remission after a single course.

What the Rituximab Label and the PEMPHIX Trial Report

The U.S. Food and Drug Administration label lists rituximab for adults with moderate to severe pemphigus vulgaris: two 1,000 mg intravenous infusions two weeks apart, together with a tapering course of steroids (glucocorticoids), then 500 mg at month 12 and every 6 months after that. In the PEMPHIX trial (Werth et al., 2021), 135 patients were randomly assigned to rituximab or to mycophenolate mofetil, both with the same tapering steroid schedule. At week 52, 40% of the rituximab group were in sustained complete remission, compared with 10% of the mycophenolate mofetil group. The rituximab group had fewer flares (6 versus 44) and used less steroid (an average total of 3,545 mg versus 5,140 mg), but serious adverse events were more common (22% versus 15%).

Efgartigimod: A Phase III Trial Without Clinical Benefit

Efgartigimod is an antibody fragment that blocks the neonatal Fc receptor, which lowers immunoglobulin G levels, including the anti-desmoglein antibodies that cause pemphigus. In the ADDRESS phase III trial (Joly et al., 2026), 222 adults with moderate-to-severe pemphigus (190 with PV, 32 with pemphigus foliaceus) received weekly efgartigimod injections or placebo, both with prednisone. By week 30, 35.5% of PV patients on efgartigimod reached complete remission on minimal prednisone (10 mg a day or less), compared with 30.3% on placebo, a difference that was not statistically significant (P = 0.60). Anti-desmoglein antibody levels fell quickly, but this did not translate into better disease scores.

Prior Steroid-Sparing Agents

Before rituximab availability, steroid-sparing was achieved with:

Maintenance and Monitoring

After achieving disease control, maintenance focuses on preventing relapse while minimizing treatment toxicity.

Paraneoplastic Pemphigus

Paraneoplastic pemphigus (PNP) is a rare and severe variant triggered by an underlying neoplasm — most commonly non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), Castleman disease, thymoma, or sarcoma. The antibodies in PNP target not only desmogleins but also plakins (envoplakin, periplakin, desmoplakin) and other structural proteins, producing a more devastating clinical picture.

PNP is distinguished from PV by:

Prognosis of PNP is poor, largely determined by the underlying malignancy. Treating the cancer may improve PNP, but bronchiolitis obliterans tends to be irreversible. Overall mortality exceeds 90%.

Prognosis and Quality of Life

The prognosis of PV has been transformed over the past 70 years:

Even with successful treatment, PV significantly impacts quality of life:

In the RITUX3 trial, 89% of patients given rituximab plus short-term prednisone were in complete remission off all therapy at 24 months, compared with 34% of those given prednisone alone. Patients not in remission require ongoing maintenance therapy or experience periodic relapses. Disease severity at diagnosis (number of body surface areas involved, oral severity, antibody titers) predicts long-term outcomes.

Key Research Papers

Key peer-reviewed studies on pemphigus vulgaris pathogenesis, diagnosis, and treatment. Each PMID link opens the study on PubMed.

  1. Joly P, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031-2040. — PubMed PMID: 28342637
  2. Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med. 2006;355(17):1800-1810. — PubMed PMID: 17065642
  3. Amagai M, et al. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 1991;67(5):869-877. — PubMed PMID: 1720352
  4. Murrell DF, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58(6):1043-1046. — PubMed PMID: 18339444
  5. Kasperkiewicz M, et al. Pemphigus. Nat Rev Dis Primers. 2017;3:17026. — PubMed PMID: 28492232
  6. Grando SA. Pemphigus autoimmunity: hypotheses and realities. Autoimmunity. 2012;45(1):7-35. — PubMed PMID: 21939410
  7. Ingen-Housz-Oro S, et al. First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids. JAMA Dermatol. 2015;151(2):200-203. — PubMed PMID: 25354242
  8. Feliciani C, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol. 2015;172(4):867-877. — PubMed PMID: 25827742
  9. Bystryn JC, Rudolph JL. Pemphigus. Lancet. 2005;366(9479):61-73. — PubMed PMID: 15993235
  10. Zhao L, Chen Y, Wang M. The global incidence rate of pemphigus vulgaris: a systematic review and meta-analysis. Dermatology. 2023;239(4):514-522. — PubMed PMID: 36944327
  11. Werth VP, Joly P, Mimouni D, et al. Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris. N Engl J Med. 2021;384(24):2295-2305. — PubMed PMID: 34097368
  12. Joly P, Murrell DF, Aoyama Y, et al. Efficacy and safety of subcutaneous efgartigimod with prednisone in moderate-to-severe pemphigus (ADDRESS): a global, phase III, randomised controlled, double-blind trial. Br J Dermatol. 2026;195(5):750-762. — PubMed PMID: 42723554

Curated PubMed topic searches:

  1. PubMed: Rituximab for PV
  2. PubMed: Desmoglein antibodies
  3. PubMed: DIF diagnosis
  4. PubMed: Corticosteroid therapy
  5. PubMed: Paraneoplastic PV
  6. PubMed: Oral mucosal PV
  7. PubMed: PV quality of life
  8. PubMed: Pemphigus foliaceus

Back to Table of Contents

Connections

Back to Table of Contents